A Comprehensive Study of Dyskeratosis Congenita: Hematopoietic Characterization, Disease Modelling and Innovative Therapies
Autor (es)
Carrascoso Rubio, CarlosEntidad
UAM. Departamento de Farmacología; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT); Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)Fecha de edición
2021-12-17Financiado por
La ejecución de este trabajo de investigación ha sido financiada con proyectos del Ministerio de Economía, Comercio y Competitividad y Fondo Europeo de Desarrollo Regional (FEDER) (SAF2015-68073-R: “Terapia génica y otras terapias innovadoras para el tratamiento de los síndromes congénitos con fallo de médula ósea”), del Ministerio de Ciencia, Innovación y Universidades y Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-097125-B-I00: “Nuevas aproximaciones terapéuticas para el tratamiento de enfermedades hereditarias de fallo de médula ósea”) y del Fondo de Investigaciones Sanitarias – Instituto de Salud Carlos III (FIS-ISCIII) (P17-01401: “Neumonitis y fibrosis pulmonar inducidas por radioterapia. Posibles tratamientos con péptidos encapsulados en nanopartículas, papel de JNK/MKP1 y del acortamiento telomérico”).Materias
Farmacología; Fisiología; Farmacia; MedicinaNota
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Farmacología. Fecha de Lectura: 17-12-2021Esta tesis tiene embargado el acceso al texto completo hasta el 17-06-2023
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Resumen
Dyskeratosis congenita (DC) is a low prevalence inherited bone marrow failure (BMF) syndrome caused by mutations in telomerase complex-related genes. Therefore, DC is also considered a telomere biology disorder. Pathogenic genetic variants have been discovered in 14 different genes and these mutations result in telomerase dysfunction leading to premature telomere shortening, which is the main molecular hallmark of DC. Clinically, DC is characterized by the mucocutaneous triad and systemic complications but BMF represents the cause of early mortality in more than 80% of the cases. Given the unawareness of the hematopoietic status of these patients, a deep characterization of peripheral blood (PB) and bone marrow (BM) samples has been conducted in this work. DC patients showed premature telomere shortening, severe pancytopenia and high percentage of erythroid progenitors in PB. Moreover, reduced content in hematopoietic stem and progenitor cells (HSPC) was observed both in PB and BM in comparison to healthy donors (HD). Considering the low number of DC patients and their limited percentage of CD34+ cells, we decided to study two different models in which innovative therapies to treat the BMF could be screened. On one hand, we evaluated the hematopoietic status of an autosomal dominant DC mouse model. Defective in vitro growth was observed in bone marrow cells of mice with mutations in Terc and naturally shortened telomeres, suggesting an incipient BMF. On the other hand, a HSPC-based model of X-linked DC (X-DC) was established through the stable inhibition of DKC1 using shRNAs delivered by lentiviral vectors (LV). Although androgens have been proposed as a potential treatment for BMF, the only curative treatment nowadays is allogeneic HSPC transplantation. However, low availability of HLA-compatible donors and risks derived from conditioning regimes have led hematologists to ask for the development of alternative therapies to treat BMF in DC patients. To address this issue, we generated two LVs expressing GSE4 peptide and evaluated their safety and efficacy in HSPCs and lymphoblastic cell lines (LCL). While in vivo and in vitro properties were not altered in HD human HSPCs, we demonstrated that the ectopic expression of GSE4 recovered several phenotypic hallmarks in X-DC patient-derived LCLs and in DKC1-interfered CD34+ cells. Finally, we have also developed a knock-in targeted gene therapy strategy to treat BMF in DC patients with mutations in exons 2-15 of the DKC1 gene. Although confirmation of homology directed repair in HD human HSPCs is still a preliminary result, we consider this approach as a promising therapeutic alternative which could be also extended to other telomerase complex-related genes. Taken together, these results have improved the knowledge surrounding a complex disorder such as DC and constitute a significant step in the development of innovative treatments for the characteristic BMF of DC patients
Lista de ficheros
Nombre
Tamaño
27.65Mb
Formato
PDF
Descripción
Texto de la Tesis Doctoral
Google Scholar:Carrascoso Rubio, Carlos
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Gene therapy and cell reprogramming in mouse models of monogenic hematopoietic stem cell diseases
Molina Estévez, Francisco Javier
2013-11-20 -
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
De La Piedra, Concepción; Alcaraz, A.; Bellmunt, Joaquim; Meseguer, Cristina; Gómez Caamaño, Antonio; Ribal, María José; Vázquez, Fernando Javier; Anido, Urbano; Samper, Pilar María; Esteban, Emilio; Álvarez-Ossorio, Jose Luis; Lara, Pedro Carlos; San José, L. A.; Contreras, José Antonio Viedma; Del Alba, Aránzazu González; González-Gragera, B.; Tabernero, Ángel J.; González Enguita, María del Carmen; Fernández, Jesús María; García-Escudero, Antonio; Gómez-Veiga, Francisco J.; Méndez, Míriam J.; Segarra, José; Virizuela, Juan Antonio; Carles, Joan; Lassa, A.; Calderero, Verónica; Constela, Manuel; Delgado, Diego Hernán; Mañas, Ana; Murias, Adolfo; Reynés, Gaspar; Rodríguez, Begoña I.; Rubio, Gustavo; Sánchez, Ernesto Sánchez; Unda, Miguel; Solsona, Eduardo; Martínez Javaloyas, J. M.; Comet-Batlle, Josep; Quicios, C.; Martín-Fernández, Marta; Mahillo, Ignacio; Moróte, Juan Moróte
2013-06-25 -
A heterologous cell model for studying the role of T-cell intracellular antigen 1 in Welander distal myopathy
Carrascoso, Isabel; Sánchez-Jiménez, Carmen; Silion, Elena; Alcalde, José; Izquierdo, José M.
2023-03-03